Enquyst Technologies Achieves Breakthrough in Monoclonal Antibody Manufacturing with Chromatography-Free Purification Platform
核心洞察
Enquyst Technologies (搜索) demonstrated its Isoelectric Point Purification (IPP) technology platform can match or exceed traditional chromatography methods for monoclonal antibody (搜索) purification while increasing product yield.
The company's internal study using a trastuzumab biosimilar showed IPP technology effectively removes Host Cell Protein (搜索) and Host Cell DNA (搜索) impurities without requiring the three cost-intensive chromatographic steps of conventional downstream processing.
Enquyst received $10.5 million in Gates Grand Challenges Program (搜索) funding as part of a NIIMBL (搜索)-led team to advance low-cost monoclonal antibody (搜索) manufacturing and plans to deliver research-use IPP systems starting in 2026.
Enquyst Technologies (搜索) has achieved a significant breakthrough in biomanufacturing by demonstrating that its patented Isoelectric Point Purification (IPP) technology platform can purify monoclonal antibodies without traditional chromatography methods, potentially transforming the economics of biotherapeutic production.
Revolutionary Approach to Antibody Purification
For several decades, chromatography has served as the cornerstone of downstream processing for monoclonal antibody (搜索) purification. Traditional downstream processing requires three cost-intensive chromatographic steps: Protein A affinity, anion exchange, and cation exchange, combined with other technologies to produce the final antibody product.
Enquyst's IPP technology platform represents a paradigm shift by eliminating these chromatographic steps entirely. In a recent internal study comparing traditional chromatography downstream processing with IPP downstream processing to isolate and purify a trastuzumab biosimilar, the company demonstrated that its technology platform met or exceeded results in removing Host Cell Protein (搜索) (HCP) and Host Cell DNA (搜索) (HC DNA) impurities while simultaneously increasing product yield.
Clinical and Manufacturing Implications
The breakthrough has significant implications for biotherapeutic manufacturing costs and accessibility. "These results clearly demonstrate the potential that our IPP technology platform has to transform the landscape of biomanufacturing," said Dr. Jason Criscione, Founder and Chief Scientific Officer of Enquyst Technologies (搜索). "We are excited to continue to push the limits of the technology to solve challenges and address unmet needs in the downstream processing of mAb and advanced therapy medicinal products."
With further optimization of its IPP technology platform, Enquyst believes it can surpass these already promising results to deliver a new standard in purity and reduced downstream processing costs for biotherapeutics.
Major Funding and Scale-Up Plans
The paradigm-shifting data positions Enquyst to deliver on its early technical milestones as a key technology partner of the NIIMBL (搜索)-led team that recently received $10.5 million in funding through the Gates Grand Challenges Program (搜索) to advance exceptionally low-cost monoclonal antibody (搜索) manufacturing. Enquyst will utilize these funds to scale up its IPP technology platform to enable large-scale, continuous monoclonal antibody manufacturing.
Commercial Timeline
Building on these developments, Enquyst is preparing to deliver its first research-use only IPP systems to collaboration partners and customers starting in 2026. This timeline represents a critical step toward commercializing the technology and making it available to the broader biomanufacturing industry.
The company's mission focuses on developing next-generation biomanufacturing and in-line analytical technology solutions to enable continuous manufacturing and provide the growing diversity of life-changing and curative treatments a viable path to the clinic with affordable costs.